GW Pharmaceuticals PLC - Price Analysis Snapshot

This Report features up to a ten-year record of the equity Price history for GW Pharmaceuticals PLC. Tabular results include the High, Low and Closing price for the quarter. There is also a calculation of percentage change in price for both Quarterly and Annual periods. Price values are adjusted for stock splits and dividends.

GW Pharmaceuticals PLC. The Group's principal activity is developing a range of new medicines based on cannabis and other controlled drugs. The Group's lead programme is the development of a portfolio of cannabinoid medicines, including Sativex, to meet patient needs in a wide range of therapeutic indications. The principal initial target areas are Multiple Sclerois (MS) spasticity, neuropathic pain, neuropathic pain in MS and cancer pain. The Group's research also includes the use of other controlled drugs in conjunction with its proprietary secure drug dispensing technology. The Group operates predominantly in the United Kingdom.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report